101ST GENERAL ASSEMBLY
State of Illinois
2019 and 2020
HB5268

 

Introduced , by Rep. John Connor

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/204  from Ch. 56 1/2, par. 1204

    Amends the Illinois Controlled Substances Act. Includes various fentanyl analogs in the list of Schedule I controlled substances.


LRB101 19113 RLC 68576 b

CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY

 

 

A BILL FOR

 

HB5268LRB101 19113 RLC 68576 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 204 as follows:
 
6    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
7    Sec. 204. (a) The controlled substances listed in this
8Section are included in Schedule I.
9    (b) Unless specifically excepted or unless listed in
10another schedule, any of the following opiates, including their
11isomers, esters, ethers, salts, and salts of isomers, esters,
12and ethers, whenever the existence of such isomers, esters,
13ethers and salts is possible within the specific chemical
14designation:
15        (1) Acetylmethadol;
16        (1.1) Acetyl-alpha-methylfentanyl
17    (N-[1-(1-methyl-2-phenethyl)-
18    4-piperidinyl]-N-phenylacetamide);
19        (2) Allylprodine;
20        (3) Alphacetylmethadol, except
21    levo-alphacetylmethadol (also known as levo-alpha-
22    acetylmethadol, levomethadyl acetate, or LAAM);
23        (4) Alphameprodine;

 

 

HB5268- 2 -LRB101 19113 RLC 68576 b

1        (5) Alphamethadol;
2        (6) Alpha-methylfentanyl
3    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
4    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
5    propanilido) piperidine;
6        (6.1) Alpha-methylthiofentanyl
7    (N-[1-methyl-2-(2-thienyl)ethyl-
8    4-piperidinyl]-N-phenylpropanamide);
9        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
10        (7.1) PEPAP
11    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
12        (8) Benzethidine;
13        (9) Betacetylmethadol;
14        (9.1) Beta-hydroxyfentanyl
15    (N-[1-(2-hydroxy-2-phenethyl)-
16    4-piperidinyl]-N-phenylpropanamide);
17        (10) Betameprodine;
18        (11) Betamethadol;
19        (12) Betaprodine;
20        (13) Clonitazene;
21        (14) Dextromoramide;
22        (15) Diampromide;
23        (16) Diethylthiambutene;
24        (17) Difenoxin;
25        (18) Dimenoxadol;
26        (19) Dimepheptanol;

 

 

HB5268- 3 -LRB101 19113 RLC 68576 b

1        (20) Dimethylthiambutene;
2        (21) Dioxaphetylbutyrate;
3        (22) Dipipanone;
4        (23) Ethylmethylthiambutene;
5        (24) Etonitazene;
6        (25) Etoxeridine;
7        (26) Furethidine;
8        (27) Hydroxpethidine;
9        (28) Ketobemidone;
10        (29) Levomoramide;
11        (30) Levophenacylmorphan;
12        (31) 3-Methylfentanyl
13    (N-[3-methyl-1-(2-phenylethyl)-
14    4-piperidyl]-N-phenylpropanamide);
15        (31.1) 3-Methylthiofentanyl
16    (N-[(3-methyl-1-(2-thienyl)ethyl-
17    4-piperidinyl]-N-phenylpropanamide);
18        (32) Morpheridine;
19        (33) Noracymethadol;
20        (34) Norlevorphanol;
21        (35) Normethadone;
22        (36) Norpipanone;
23        (36.1) Para-fluorofentanyl
24    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
25    4-piperidinyl]propanamide);
26        (37) Phenadoxone;

 

 

HB5268- 4 -LRB101 19113 RLC 68576 b

1        (38) Phenampromide;
2        (39) Phenomorphan;
3        (40) Phenoperidine;
4        (41) Piritramide;
5        (42) Proheptazine;
6        (43) Properidine;
7        (44) Propiram;
8        (45) Racemoramide;
9        (45.1) Thiofentanyl
10    (N-phenyl-N-[1-(2-thienyl)ethyl-
11    4-piperidinyl]-propanamide);
12        (46) Tilidine;
13        (47) Trimeperidine;
14        (48) Beta-hydroxy-3-methylfentanyl (other name:
15    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
16    N-phenylpropanamide);
17        (49) Furanyl fentanyl (FU-F);
18        (50) Butyryl fentanyl;
19        (51) Valeryl fentanyl;
20        (52) Acetyl fentanyl;
21        (53) Beta-hydroxy-thiofentanyl;
22        (54) 3,4-dichloro-N-[2-
23    (dimethylamino)cyclohexyl]-N-
24    methylbenzamide (U-47700); 
25        (55) 4-chloro-N-[1-[2-
26    (4-nitrophenyl)ethyl]-2-piperidinylidene]-

 

 

HB5268- 5 -LRB101 19113 RLC 68576 b

1    benzenesulfonamide (W-18); 
2        (56) 4-chloro-N-[1-(2-phenylethyl)
3    -2-piperidinylidene]-benzenesulfonamide (W-15); 
4        (57) acrylfentanyl (acryloylfentanyl); . 
5    (b-5) Fentanyl analogs, including any compound, except
6compounds scheduled elsewhere in this Act, structurally
7derived from fentanyl by replacement of the phenyl portion of
8the phenethyl group by any monocycle whether or not further
9substituted in or on the monocycle; by substitution in or on
10the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halo,
11haloalkyl, amino or nitro groups; by substitution in or on the
12piperidine ring with alkyl, alkenyl, alkoxy, ester, ether,
13hydroxy, halo, haloalkyl, amino or nitro groups; by replacement
14of the aniline ring with any aromatic monocycle whether or not
15further substituted in or on the aromatic monocycle; by
16replacement of the N-propionyl group by another acyl group; or
17by any combination of these modifications. Substances
18specified under this subsection include all of the following:
19        (1) Cyclopentyl fentanyl
20    (N-(1-phenethylpiperidin-4-yl)-N-
21    phenylcyclopentanecarboxamide); 
22        (2) 4-fluorobutyryl fentanyl (N-
23    (4-fluorophenyl)-N-[1-(2-phenylethyl)
24    piperidin-4-yl]-butyramide); 
25        (3) Isobutyryl fentanyl (2-methyl-N-phenyl-
26    N-[1-(2-phenylethyl)piperidin-4-yl]

 

 

HB5268- 6 -LRB101 19113 RLC 68576 b

1    -propanamide); 
2        (4) Methoxyacetyl fentanyl (2-methoxy-
3    N-phenyl-N-[1-(2-phenylethyl)piperidin
4    -4-yl]-acetamide); 
5        (5) 3-methylbutyryl fentanyl(N-
6    [3-methyl-1-(2-phenylethyl)piperidin
7    -4-yl]-N-phenylbutyramide); 
8        (6) 4-methoxybutyryl fentanyl (N-
9    (4-methoxyphenyl)-N-(1-phenethylpiperidin
10    -4-yl)butyramide); 
11        (7) Ocfentanil (N-(2-fluorophenyl)-2-
12    methoxy-N-[1-(2-phenylethyl)piperidin
13    -4-yl]-acetamide); 
14        (8) Tetrahydrofuran fentanyl(N-
15    (1-phenethylpiperidin-4-yl)-N-
16    phenyltetrahydrofuran-2-carboxamide); 
17        (9) Valeryl fentanyl (N-phenyl-N-
18    [1-(2-phenylethyl)piperidin-4-yl]pentanamide). 
19    (c) Unless specifically excepted or unless listed in
20another schedule, any of the following opium derivatives, its
21salts, isomers and salts of isomers, whenever the existence of
22such salts, isomers and salts of isomers is possible within the
23specific chemical designation:
24        (1) Acetorphine;
25        (2) Acetyldihydrocodeine;
26        (3) Benzylmorphine;

 

 

HB5268- 7 -LRB101 19113 RLC 68576 b

1        (4) Codeine methylbromide;
2        (5) Codeine-N-Oxide;
3        (6) Cyprenorphine;
4        (7) Desomorphine;
5        (8) Diacetyldihydromorphine (Dihydroheroin);
6        (9) Dihydromorphine;
7        (10) Drotebanol;
8        (11) Etorphine (except hydrochloride salt);
9        (12) Heroin;
10        (13) Hydromorphinol;
11        (14) Methyldesorphine;
12        (15) Methyldihydromorphine;
13        (16) Morphine methylbromide;
14        (17) Morphine methylsulfonate;
15        (18) Morphine-N-Oxide;
16        (19) Myrophine;
17        (20) Nicocodeine;
18        (21) Nicomorphine;
19        (22) Normorphine;
20        (23) Pholcodine;
21        (24) Thebacon.
22    (d) Unless specifically excepted or unless listed in
23another schedule, any material, compound, mixture, or
24preparation which contains any quantity of the following
25hallucinogenic substances, or which contains any of its salts,
26isomers and salts of isomers, whenever the existence of such

 

 

HB5268- 8 -LRB101 19113 RLC 68576 b

1salts, isomers, and salts of isomers is possible within the
2specific chemical designation (for the purposes of this
3paragraph only, the term "isomer" includes the optical,
4position and geometric isomers):
5        (1) 3,4-methylenedioxyamphetamine
6    (alpha-methyl,3,4-methylenedioxyphenethylamine,
7    methylenedioxyamphetamine, MDA);
8        (1.1) Alpha-ethyltryptamine
9    (some trade or other names: etryptamine;
10    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
11    3-(2-aminobutyl)indole; a-ET; and AET);
12        (2) 3,4-methylenedioxymethamphetamine (MDMA);
13        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
14    (also known as: N-ethyl-alpha-methyl-
15    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
16    and MDEA);
17        (2.2) N-Benzylpiperazine (BZP);
18        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
19        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
20        (4) 3,4,5-trimethoxyamphetamine (TMA);
21        (5) (Blank);
22        (6) Diethyltryptamine (DET);
23        (7) Dimethyltryptamine (DMT);
24        (7.1) 5-Methoxy-diallyltryptamine;
25        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
26        (9) Ibogaine  (some trade and other names:

 

 

HB5268- 9 -LRB101 19113 RLC 68576 b

1    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
2    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
3    indole; Tabernanthe iboga);
4        (10) Lysergic acid diethylamide;
5        (10.1) Salvinorin A;
6        (10.5) Salvia divinorum (meaning all parts of the plant
7    presently classified botanically as Salvia divinorum,
8    whether growing or not, the seeds thereof, any extract from
9    any part of that plant, and every compound, manufacture,
10    salts, isomers, and salts of isomers whenever the existence
11    of such salts, isomers, and salts of isomers is possible
12    within the specific chemical designation, derivative,
13    mixture, or preparation of that plant, its seeds or
14    extracts);
15        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
16        (12) Peyote (meaning all parts of the plant presently
17    classified botanically as Lophophora williamsii Lemaire,
18    whether growing or not, the seeds thereof, any extract from
19    any part of that plant, and every compound, manufacture,
20    salts, derivative, mixture, or preparation of that plant,
21    its seeds or extracts);
22        (13) N-ethyl-3-piperidyl benzilate (JB 318);
23        (14) N-methyl-3-piperidyl benzilate;
24        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
25    (also known as N-hydroxy-alpha-methyl-
26    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

 

 

HB5268- 10 -LRB101 19113 RLC 68576 b

1        (15) Parahexyl; some trade or other names:
2    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
3    dibenzo (b,d) pyran; Synhexyl;
4        (16) Psilocybin;
5        (17) Psilocyn;
6        (18) Alpha-methyltryptamine (AMT);
7        (19) 2,5-dimethoxyamphetamine
8    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
9        (20) 4-bromo-2,5-dimethoxyamphetamine
10    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
11    4-bromo-2,5-DMA);
12        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
13    Some trade or other names: 2-(4-bromo-
14    2,5-dimethoxyphenyl)-1-aminoethane;
15    alpha-desmethyl DOB, 2CB, Nexus;
16        (21) 4-methoxyamphetamine
17    (4-methoxy-alpha-methylphenethylamine;
18    paramethoxyamphetamine; PMA);
19        (22) (Blank);
20        (23) Ethylamine analog of phencyclidine.
21    Some trade or other names:
22    N-ethyl-1-phenylcyclohexylamine,
23    (1-phenylcyclohexyl) ethylamine,
24    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
25        (24) Pyrrolidine analog of phencyclidine. Some trade
26    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,

 

 

HB5268- 11 -LRB101 19113 RLC 68576 b

1    PHP;
2        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
3        (26) 2,5-dimethoxy-4-ethylamphetamine
4    (another name: DOET);
5        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
6    (another name: TCPy);
7        (28) (Blank);
8        (29) Thiophene analog of phencyclidine (some trade
9    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
10    2-thienyl analog of phencyclidine; TPCP; TCP);
11        (29.1) Benzothiophene analog of phencyclidine. Some
12    trade or other names: BTCP or benocyclidine;
13        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
14        (30) Bufotenine (some trade or other names:
15    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
16    3-(2-dimethylaminoethyl)-5-indolol;
17    5-hydroxy-N,N-dimethyltryptamine;
18    N,N-dimethylserotonin; mappine);
19        (31) (Blank);  
20        (32) (Blank);  
21        (33) (Blank);  
22        (34) (Blank); 
23        (34.5) (Blank);  
24        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
25    (2-methyloctan-2-yl)-6a,7, 
26    10,10a-tetrahydrobenzo[c]chromen-1-ol

 

 

HB5268- 12 -LRB101 19113 RLC 68576 b

1    Some trade or other names: HU-210; 
2        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
3    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
4    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
5    salts, and salts of isomers; Some trade or other  
6    names: HU-210, Dexanabinol; 
7        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
8    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
9    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
10    Some trade or other names: HU-211;
11        (37) (Blank);
12        (38) (Blank);
13        (39) (Blank);
14        (40) (Blank);
15        (41) (Blank);
16        (42) Any compound structurally derived from
17    3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
18    by substitution at the nitrogen atom of the indole ring by
19    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20    cycloalkylethyl, aryl halide, alkyl aryl halide,
21    1-(N-methyl-2-piperidinyl)methyl, or
22    2-(4-morpholinyl)ethyl whether or not further substituted
23    in the indole ring to any extent, whether or not
24    substituted in the naphthyl ring to any extent. Examples of
25    this structural class include, but are not limited to,
26    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

 

 

HB5268- 13 -LRB101 19113 RLC 68576 b

1        (43) Any compound structurally derived from
2    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
3    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
4    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5    halide, 1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    in the pyrrole ring to any extent, whether or not
8    substituted in the naphthyl ring to any extent. Examples of
9    this structural class include, but are not limited to,
10    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
11        (44) Any compound structurally derived from
12    1-(1-naphthylmethyl)indene by substitution at the
13    3-position of the indene ring by alkyl, haloalkyl, alkenyl,
14    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15    halide, 1-(N-methyl-2-piperidinyl)methyl, or
16    2-(4-morpholinyl)ethyl whether or not further substituted
17    in the indene ring to any extent, whether or not
18    substituted in the naphthyl ring to any extent. Examples of
19    this structural class include, but are not limited to,
20    JWH-176;
21        (45) Any compound structurally derived from
22    3-phenylacetylindole by substitution at the nitrogen atom
23    of the indole ring with alkyl, haloalkyl, alkenyl,
24    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
25    halide, 1-(N-methyl-2-piperidinyl)methyl, or
26    2-(4-morpholinyl)ethyl, whether or not further substituted

 

 

HB5268- 14 -LRB101 19113 RLC 68576 b

1    in the indole ring to any extent, whether or not
2    substituted in the phenyl ring to any extent. Examples of
3    this structural class include, but are not limited to,
4    JWH-167, JWH-250, JWH-251, and RCS-8;
5        (46) Any compound structurally derived from
6    2-(3-hydroxycyclohexyl)phenol by substitution at the
7    5-position of the phenolic ring by alkyl, haloalkyl,
8    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
9    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
10    2-(4-morpholinyl)ethyl, whether or not substituted in the
11    cyclohexyl ring to any extent. Examples of this structural
12    class include, but are not limited to, CP 47, 497 and its
13    C8 homologue (cannabicyclohexanol);
14        (46.1) Any compound structurally derived from
15    3-(benzoyl) indole with substitution at the nitrogen atom
16    of the indole ring by an alkyl, haloalkyl, alkenyl,
17    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18    halide, 1-(N-methyl-2-piperidinyl)methyl, or
19    2-(4-morpholinyl)ethyl group whether or not further
20    substituted in the indole ring to any extent and whether or
21    not substituted in the phenyl ring to any extent. Examples
22    of this structural class include, but are not limited to,
23    AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and
24    RCS-4;
25        (47) (Blank);
26        (48) (Blank);

 

 

HB5268- 15 -LRB101 19113 RLC 68576 b

1        (49) (Blank);
2        (50) (Blank);
3        (51) (Blank);
4        (52) (Blank);
5        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
6    Some trade or other names: 2C-T-7;
7        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some trade
8    or other names: 2C-E;
9        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
10    trade or other names: 2C-D;
11        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
12    trade or other names: 2C-C;
13        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
14    or other names: 2C-I;
15        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
16    trade or other names: 2C-T-2;
17        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
18    Some trade or other names: 2C-T-4;
19        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
20    other names: 2C-H;
21        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some trade
22    or other names: 2C-N;
23        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
24    trade or other names: 2C-P;
25        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. Some
26    trade or other names: 2C-G;

 

 

HB5268- 16 -LRB101 19113 RLC 68576 b

1        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
2    phenethylamine referred to in subparagraphs (20.1), (53),
3    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
4    (53.8), (53.9), and (53.10) including, but not limited to,
5    25I-NBOMe and 25C-NBOMe;
6        (54) 5-Methoxy-N,N-diisopropyltryptamine;
7        (55) (Blank);
8        (56) (Blank);
9        (57) (Blank);
10        (58) (Blank);
11        (59) 3-cyclopropoylindole with substitution at the
12    nitrogen atom of the indole ring by alkyl, haloalkyl,
13    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
14    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl, whether or not further substituted
16    on the indole ring to any extent, whether or not
17    substituted on the cyclopropyl ring to any extent:
18    including, but not limited to, XLR11, UR144, FUB-144;
19        (60) 3-adamantoylindole with substitution at the
20    nitrogen atom of the indole ring by alkyl, haloalkyl,
21    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
22    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
23    2-(4-morpholinyl)ethyl, whether or not further substituted
24    on the indole ring to any extent, whether or not
25    substituted on the adamantyl ring to any extent: including,
26    but not limited to, AB-001;

 

 

HB5268- 17 -LRB101 19113 RLC 68576 b

1        (61) N-(adamantyl)-indole-3-carboxamide with
2    substitution at the nitrogen atom of the indole ring by
3    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
4    cycloalkylethyl, aryl halide, alkyl aryl halide,
5    1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    on the indole ring to any extent, whether or not
8    substituted on the adamantyl ring to any extent: including,
9    but not limited to, APICA/2NE-1, STS-135;
10        (62) N-(adamantyl)-indazole-3-carboxamide with
11    substitution at a nitrogen atom of the indazole ring by
12    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
13    cycloalkylethyl, aryl halide, alkyl aryl halide,
14    1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl, whether or not further substituted
16    on the indazole ring to any extent, whether or not
17    substituted on the adamantyl ring to any extent: including,
18    but not limited to, AKB48, 5F-AKB48;
19        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
20    with substitution at the nitrogen atom of the indole ring
21    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
22    cycloalkylethyl, aryl halide, alkyl aryl halide,
23    1-(N-methyl-2-piperidinyl)methyl, or
24    2-(4-morpholinyl)ethyl, whether or not further substituted
25    on the indole ring to any extent, whether or not
26    substituted on the quinoline ring to any extent: including,

 

 

HB5268- 18 -LRB101 19113 RLC 68576 b

1    but not limited to, PB22, 5F-PB22, FUB-PB-22;
2        (64) 3-(1-naphthoyl)indazole with substitution at the
3    nitrogen atom of the indazole ring by alkyl, haloalkyl,
4    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
5    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    on the indazole ring to any extent, whether or not
8    substituted on the naphthyl ring to any extent: including,
9    but not limited to, THJ-018, THJ-2201;
10        (65) 2-(1-naphthoyl)benzimidazole with substitution at
11    the nitrogen atom of the benzimidazole ring by alkyl,
12    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
13    aryl halide, alkyl aryl halide,
14    1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl, whether or not further substituted
16    on the benzimidazole ring to any extent, whether or not
17    substituted on the naphthyl ring to any extent: including,
18    but not limited to, FUBIMINA;
19        (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
20    3-carboxamide with substitution on the nitrogen atom of the
21    indazole ring by alkyl, haloalkyl, alkenyl,
22    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23    halide, 1-(N-methyl-2-piperidinyl)methyl, or
24    2-(4-morpholinyl)ethyl, whether or not further substituted
25    on the indazole ring to any extent: including, but not
26    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

 

 

HB5268- 19 -LRB101 19113 RLC 68576 b

1        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
2    indazole-3-carboxamide with substitution on the nitrogen
3    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
4    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5    halide, 1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    on the indazole ring to any extent: including, but not
8    limited to, ADB-PINACA, ADB-FUBINACA;
9        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
10    indole-3-carboxamide with substitution on the nitrogen
11    atom of the indole ring by alkyl, haloalkyl, alkenyl,
12    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13    halide, 1-(N-methyl-2-piperidinyl)methyl, or
14    2-(4-morpholinyl)ethyl, whether or not further substituted
15    on the indole ring to any extent: including, but not
16    limited to, ADBICA, 5F-ADBICA;
17        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
18    3-carboxamide with substitution on the nitrogen atom of the
19    indole ring by alkyl, haloalkyl, alkenyl,
20    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
21    halide, 1-(N-methyl-2-piperidinyl)methyl, or
22    2-(4-morpholinyl)ethyl, whether or not further substituted
23    on the indole ring to any extent: including, but not
24    limited to, ABICA, 5F-ABICA;
25        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
26    methylbutanoate with substitution on the nitrogen atom of

 

 

HB5268- 20 -LRB101 19113 RLC 68576 b

1    the indazole ring by alkyl, haloalkyl, alkenyl,
2    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3    halide, 1-(N-methyl-2-piperidinyl)methyl, or
4    2-(4-morpholinyl)ethyl, whether or not further substituted
5    on the indazole ring to any extent: including, but not
6    limited to, AMB, 5F-AMB;
7        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
8    dimethylbutanoate with substitution on the nitrogen atom
9    of the indazole ring by alkyl, haloalkyl, alkenyl,
10    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11    halide, 1-(N-methyl-2-piperidinyl)methyl, or
12    2-(4-morpholinyl)ethyl, whether or not further substituted
13    on the indazole ring to any extent: including, but not
14    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
15        (72) Methyl 2-(1H-indole-3-carboxamido)-3-
16    methylbutanoate with substitution on the nitrogen atom of
17    the indole ring by alkyl, haloalkyl, alkenyl,
18    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
19    halide, 1-(N-methyl-2-piperidinyl)methyl, or
20    2-(4-morpholinyl)ethyl, whether or not further substituted
21    on the indazole ring to any extent: including, but not
22    limited to, MMB018, MMB2201, and AMB-CHMICA;
23        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
24    dimethylbutanoate with substitution on the nitrogen atom
25    of the indole ring by alkyl, haloalkyl, alkenyl,
26    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl

 

 

HB5268- 21 -LRB101 19113 RLC 68576 b

1    halide, 1-(N-methyl-2-piperidinyl)methyl, or
2    2-(4-morpholinyl)ethyl, whether or not further substituted
3    on the indazole ring to any extent: including, but not
4    limited to, MDMB-CHMICA;
5        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
6    indazole-3-carboxamide with substitution on the nitrogen
7    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
8    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
9    halide, 1-(N-methyl-2-piperidinyl)methyl, or
10    2-(4-morpholinyl)ethyl, whether or not further substituted
11    on the indazole ring to any     extent: including, but not
12    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
13        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
14    3-carboxamide with substitution on the nitrogen atom of the
15    indole ring by alkyl, haloalkyl, alkenyl,
16    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17    halide, 1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl, whether or not further substituted
19    on the indazole ring to any extent: including, but not
20    limited to, APP-PICA and 5-fluoro-APP-PICA;
21        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
22    4-AcO-DMT;
23        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
24    name 5-MeO-MIPT;
25        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
26        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

 

 

HB5268- 22 -LRB101 19113 RLC 68576 b

1        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
2        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
3    (4-HO-MiPT);
4        (82) Fluorophenylpiperazine;
5        (83) Methoxetamine;
6        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
7    ethcathinone).
8    (e) Unless specifically excepted or unless listed in
9another schedule, any material, compound, mixture, or
10preparation which contains any quantity of the following
11substances having a depressant effect on the central nervous
12system, including its salts, isomers, and salts of isomers
13whenever the existence of such salts, isomers, and salts of
14isomers is possible within the specific chemical designation:
15        (1) mecloqualone;
16        (2) methaqualone; and
17        (3) gamma hydroxybutyric acid.
18    (f) Unless specifically excepted or unless listed in
19another schedule, any material, compound, mixture, or
20preparation which contains any quantity of the following
21substances having a stimulant effect on the central nervous
22system, including its salts, isomers, and salts of isomers:
23        (1) Fenethylline;
24        (2) N-ethylamphetamine;
25        (3) Aminorex (some other names:
26    2-amino-5-phenyl-2-oxazoline; aminoxaphen;

 

 

HB5268- 23 -LRB101 19113 RLC 68576 b

1    4-5-dihydro-5-phenyl-2-oxazolamine) and its
2    salts, optical isomers, and salts of optical isomers;
3        (4) Methcathinone (some other names:
4    2-methylamino-1-phenylpropan-1-one;
5    Ephedrone; 2-(methylamino)-propiophenone;
6    alpha-(methylamino)propiophenone; N-methylcathinone;
7    methycathinone; Monomethylpropion; UR 1431) and its
8    salts, optical isomers, and salts of optical isomers;
9        (5) Cathinone (some trade or other names:
10    2-aminopropiophenone; alpha-aminopropiophenone;
11    2-amino-1-phenyl-propanone; norephedrone);
12        (6) N,N-dimethylamphetamine (also known as:
13    N,N-alpha-trimethyl-benzeneethanamine;
14    N,N-alpha-trimethylphenethylamine);
15        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
16    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
17        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
18        (9) Halogenated amphetamines and
19    methamphetamines - any compound derived from either
20    amphetamine or methamphetamine through the substitution
21    of a halogen on the phenyl ring, including, but not
22    limited to, 2-fluoroamphetamine, 3-
23    fluoroamphetamine and 4-fluoroamphetamine; 
24        (10) Aminopropylbenzofuran (APB):
25    including 4-(2-Aminopropyl) benzofuran, 5-
26    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

 

 

HB5268- 24 -LRB101 19113 RLC 68576 b

1    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
2        (11) Aminopropyldihydrobenzofuran (APDB):
3    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
4    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
5    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
6    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
7        (12) Methylaminopropylbenzofuran
8    (MAPB): including 4-(2-methylaminopropyl)
9    benzofuran, 5-(2-methylaminopropyl)benzofuran,
10    6-(2-methylaminopropyl)benzofuran
11    and 7-(2-methylaminopropyl)benzofuran. 
12    (g) Temporary listing of substances subject to emergency
13scheduling. Any material, compound, mixture, or preparation
14that contains any quantity of the following substances:
15        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
16    (benzylfentanyl), its optical isomers, isomers, salts, and
17    salts of isomers;
18        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
19    phenylpropanamide (thenylfentanyl), its optical isomers,
20    salts, and salts of isomers.
21    (h) Synthetic cathinones. Unless specifically excepted,
22any chemical compound which is not approved by the United
23States Food and Drug Administration or, if approved, is not
24dispensed or possessed in accordance with State or federal law,
25not including bupropion, structurally derived from
262-aminopropan-1-one by substitution at the 1-position with

 

 

HB5268- 25 -LRB101 19113 RLC 68576 b

1either phenyl, naphthyl, or thiophene ring systems, whether or
2not the compound is further modified in one or more of the
3following ways:
4        (1) by substitution in the ring system to any extent
5    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
6    halide substituents, whether or not further substituted in
7    the ring system by one or more other univalent
8    substituents. Examples of this class include, but are not
9    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
10        (2) by substitution at the 3-position with an acyclic
11    alkyl substituent. Examples of this class include, but are
12    not limited to, 2-methylamino-1-phenylbutan-1-one
13    (buphedrone); or
14        (3) by substitution at the 2-amino nitrogen atom with
15    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
16    inclusion of the 2-amino nitrogen atom in a cyclic
17    structure. Examples of this class include, but are not
18    limited to, Dimethylcathinone, Ethcathinone, and
19    a-Pyrrolidinopropiophenone (a-PPP); or
20    Any other synthetic cathinone which is not approved by the
21United States Food and Drug Administration or, if approved, is
22not dispensed or possessed in accordance with State or federal
23law.
24    (i) Synthetic cannabinoids or piperazines. Any synthetic
25cannabinoid or piperazine which is not approved by the United
26States Food and Drug Administration or, if approved, which is

 

 

HB5268- 26 -LRB101 19113 RLC 68576 b

1not dispensed or possessed in accordance with State and federal
2law.
3(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
4100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
58-14-18.)